NOI -Illumina Infinium Methylation Screening Array
Closed Solicitation Posted
- Solicitation number
- 75N98026Q00600
- Agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health, Office of the Director, Office of Acquisitions, intends to award a firm-fixed-price purchase order on a non-competitive basis to Illumina, Inc. for twenty Infinium Methylation Screening Array-48 Kits, with responses due June 18, 2026. This is a sole-source, brand-name acquisition under FAR 12.603 and FAR 6.302-3(a)(2)(ii), not expected to exceed the simplified acquisition threshold.
Illumina is the sole manufacturer of the Infinium Methylation Screening Array, a proprietary BeadChip product protected by patents and trade secrets, and the only methylation array compatible with the Illumina iScan System and Infinium Automated Pipelling System with ILASS already installed at the NIA Laboratory of Neurogenetics. No other manufacturer produces a functionally equivalent product, and Illumina has certified in writing that it has not authorized any third-party intermediary to provide the required products.
Delivery is to NIH NIA Laboratory of Neurogenetics, 35 Convent Drive, Building 35, Room 1A-215, Bethesda, Maryland, as soon as possible following award but no later than December 30, 2026, under Delivered at Place terms. The period of performance runs from June 19, 2026 to December 31, 2026. Each kit contains a 48-sample BeadChip and all required reagents for the EX Methylation Assay after bisulfite conversion, interrogating approximately 270,000 CpG methylation sites. The kits will support an epigenome-wide association study of DNA methylation patterns and cardiovascular disease mortality risk within the NHLBI Division of Intramural Research, Laboratory of Genomic Instability and Cardiopulmonary Outcomes. Offerors must provide product information, catalog/model numbers, documentation of salient characteristics, quantity, estimated price, shipping and handling charges, delivery timeframe, UEI, TIN, and business size certification, and must be actively registered in SAM.gov. The government reserves the right to accept responses from all responsible sources and will make a final determination on competition at its sole discretion.
Notice text
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued.
(ii) The solicitation number is 75N98026Q00600. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (brand-name).
This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii).
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122 for twenty (20) Infinium Methylation Screening Array-48 Kits (Catalog No. 20112611) in support of the NHLBI Division of Intramural Research, Laboratory of Genomic Instability and Cardiopulmonary Outcomes (LoGICO). Illumina is the sole manufacturer and source of the Infinium Methylation Screening Array, a proprietary BeadChip product protected by patents and trade secrets, and the only methylation array compatible with the Illumina iScan System and Infinium Automated Pipetting System with ILASS already installed at the NIA Laboratory of Neurogenetics where the assays will be performed. No other manufacturer produces a functionally equivalent product, and Illumina has certified in writing that it has not authorized any third-party intermediary to provide the Illumina products required for this transaction (Quotation No. 4791799).
(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026.
(iv) The associated NAICS code is 325413 ¿ In-Vitro Diagnostic Substance Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
Files
| File | Type | Posted |
|---|---|---|
| Sol_75N98026Q00600.pdf |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity